Alkermes wins FDA fast track; Aslan raises $22M for R&D work; The genetics of negative thinking

@FierceBiotech: Popular yesterday: 10 top drugs in biopharma's late-stage pipeline. Feature | Follow @FierceBiotech

@JohnCFierce: Few months after $60M C series and Forest deal, Trevena files for $86M IPO. SEC filing | Press release | Follow @JohnCFierce

@DamianFierce: MacroGenics has up-sized its IPO, now seeking $80M amid biotech blitz. ICYMI yesterday | Follow @DamianFierce

@EmilyMFierce: 3-D printing builds bacterial metropolises. More via ScienceNews | Follow @EmilyMFierce

> The FDA is putting Alkermes' ($ALKS) ALKS 5461 on the fast track. The biotech company is developing the drug for major depression. Release

> Singapore-based Aslan Pharmaceuticals has raised $22 million in a Series B. The biotech's model is to in-license preclinical therapies, take them through Phase II and then partner them out. Story

Medical Device News

@FierceMedDev: Medtronic jumps into hemodialysis business through India partnership. ICYMI yesterday | Follow @FierceMedDev

@MarkHFierce: The head of Roche molecular diagnostics spoke to FierceDiagnostics recently about two key future products. More | Follow @MarkHFierce

@MichaelGFierce: Check out this week's FierceDrugDelivery newsletter! RNAi roundup & stem cell drug delivery action. Report | Follow @MichaelGFierce

> Are medical device companies invited to the biotech IPO party? Editor's corner

> Boston Scientific kicks off drug-eluting stent trial as sales wane. Story

> Quest warns reimbursement pressures, test volume declines will dampen Q3. More

> FDA panel casts doubt on CardioMEMS' heart failure diagnostic. Article

Pharma News

@FiercePharma: Top 10 Drugmakers in Emerging Markets--our latest special report. Feature | Follow @FiercePharma

@CarlyHFierce: Teva: Copying GlaxoSmithKline's Advair too tough for success before 2018. ICYMI yesterday | Follow @CarlyHFierce

> Which new drugs promise to shake up markets the most? Report

> Express Scripts stops covering key Big Pharma drugs on cost-effectiveness grounds. Story

> Teva plots 5,000 more job cuts in $2B savings drive. News

Pharma Manufacturing News

@EricPFierce: Will McKesson and AmerisourceBergen now face off in Europe? Article | Follow @EricPFierce

> Catalent moves on Brazil VMS, softgel market. News

> Vetter putting $100M into its production network. Report

> Teva looks for big savings from procurement, manufacturing. Story

> Feds fight drug imports Maine now allows. More

> BioCentury finds FDA has $270M in GDUFA, PDUFA fees in hand. Item

Vaccines News

> WHO prequalification moves China into global vaccine arena. Item

> Novartis opening vaccine R&D lab in North Carolina. Report

> Takeda's norovirus vaccine misses endpoint in early-phase trial. Story

> GSK targets 2015 launch for malaria vaccine. Article

> HIV trial follow-up quashes fears of infection risk. More

And Finally… Drawn to the dark side? You may be genetically predisposed. Release

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.